- This event has passed.
Biomedical Seminar Series
September 18, 2018 @ 12:00 pm - 1:00 pm
The ATR Signaling Circuitry: From Basic Research to Targeted Cancer Therapy will be presented by Lee Zou, Ph.D., Professor of Pathology at Harvard Medical School and the Associate Scientific Director at the Cancer Center at Massachusetts General Hospital.
Cancer is a complex disease driven by genetic and epigenetic alterations in the genome. To prevent these detrimental alterations, cells have evolved an intricate signaling network, called the checkpoint, to detect and signal problems in the genome. During cancer development, the activation of oncogenes and loss of tumor suppressors leads to genomic instability, rendering cancer cells increasingly dependent upon specific DNA repair and checkpoint signaling proteins to survive. The Zou laboratory is particularly interested in understanding how the checkpoint detects DNA damage and genomic instability, and how the checkpoint can be targeted in cancer therapy. Our current studies are focused on the activation of ATR and ATM, the master sensor kinases of two major checkpoint pathways. Furthermore, we are developing new strategies to exploit the genomic instability and checkpoint addiction of different cancer cells in targeted cancer therapy.
If you are interested in a one-on-one meeting with Dr. Zou, please sign up here.
Questions? Contact Breezy Tottenhoff.